Nandini Patel

Nandini is a seasoned pharmaceutical scientist with over 20 years of experience leading small molecule drug discovery and development across diverse therapeutic areas including oncology, neuroscience, internal medicine, and anti-infectives. At Pfizer, she played a pivotal role in the discovery and development of three marketed therapies - Paxlovid, Daurismo, and Fakzynja (licensed to Verastem Oncology) - as well as an upcoming second-generation COVID-19 treatment, driving programs from exploratory phases through regulatory approval.

From molecules to medicine, Nandini’s expertise in medicinal chemistry, biopharmaceutics, and drug product design fuels the rapid development and delivery of patient-centric therapies. Recognized for her innovative approaches and cross-functional leadership, she has co-authored over 30 peer-reviewed publications and patents, along with four book chapters. Her strategic insights and scientific rigor were instrumental in the accelerated development and global success of Paxlovid under unprecedented timelines.

Beyond her clinical achievements, Nandini continues to influence the field through translational innovation and data-driven decision-making, shaping the future of small molecule therapeutics. She also contributes to the pharmaceutical landscape through mentorship, thought leadership, and a steadfast commitment to advancing public health.